Buscar
Mostrando ítems 1-2 de 2
Artículo
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results
(Lippincott Williams & Wilkins, 2017)
Background: Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory diseases. The advent of biosimilar treatment options such as CT-P13 promises to improve the ...
Artículo
Knowledge of disease and access to a specialist reported by Spanish patients with ulcerative colitis. UC-LIFE survey
(Aran Ediciones S.A., 2017)
colitis (UC) about their disease and access to a specialist are important to improve health outcomes. Our objective was to determine, by collecting information directly from the patients, their information sources ...